No change in plasma residual viremia level or in HIV cellular reservoir after 1 year of treatment with DTG+3TC1

Assessing the efficacy and tolerability of DTG+3TC in HIV-1 viral suppressed patients: ANRS 167 Lamidol study1

Lamidol is a non comparative, open-label, single-arm, multicentre trial with 2 phases.

The objective was to assess the efficacy and tolerability of DTG+3TC in HIV-1 viral suppressed patients.

The primary endpoint was the proportion of patients with treatment success* at week 48. The 97% (101/104) of patient maintained viral suppression up to week 48.

Between Week 0 and Week 48, no change was observed in plasma residual viremia level or in HIV cellular reservoir size with stable plasma DTG Cmin.1

Find more at CROI 2019 website

* Treatment success = not experiencing treatment failure defined as: having changed or stopped assigned treatment; being lost to follow-up; having VF (confirmed HIV-1 RNA >50 c/mL)

  1. Charpentier C et al., Abstract 491, Presented at Conference on Retroviruses and Opportunistic Infections; March 4-7, 2019; Seattle, WA

PM-GB-DLT-WCNT-190001 - March 2019